Metagenomi Therapeutics - Public Comps and Valuation Multiples

Metagenomi Therapeutics Overview

About Metagenomi Therapeutics

Metagenomi Therapeutics Inc formerly, Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A, Refractory Hypertension, Cardiovascular diseases, and others.

Founded

2016

HQ

Employees

202

Website

metagenomi.co

Sectors

Drug Development & Therapeutics
Genomics & Personalized Medicine
BioTech
DeepTech

Financials

LTM Revenue $28.6M

LTM EBITDA -$93.5M

EV

-$77.5M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Metagenomi Therapeutics Financials

As of December 2025, Metagenomi Therapeutics reported last 12-month revenue of $28.6M and EBITDA of -$93.5M.

In the same period, Metagenomi Therapeutics achieved -$86.1M in LTM net income.

See Metagenomi Therapeutics valuation multiples based on analyst estimates

Metagenomi Therapeutics P&L

In the most recent fiscal year, Metagenomi Therapeutics reported revenue of $52.3M and EBITDA of -$83.5M.

Metagenomi Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Metagenomi Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$28.6M	XXX	$52.3M	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	-$93.5M	XXX	-$83.5M	XXX	XXX	XXX
EBITDA Margin	-327%	XXX	-160%	XXX	XXX	XXX
EBIT	-$95.5M	XXX	-$88.9M	XXX	XXX	XXX
EBIT Margin	-333%	XXX	-170%	XXX	XXX	XXX
Net Profit	-$86.1M	XXX	-$78.1M	XXX	XXX	XXX
Net Margin	-301%	XXX	-149%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Metagenomi Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $28.6M. EBITDA for the last twelve months was -$93.5M. In the most recent fiscal year, Metagenomi Therapeutics achieved $52.3M in revenue and -$83.5M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$28.6M	Analyst estimates available to subscribers	$52.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	NaN% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$93.5M	Analyst estimates available to subscribers	-$83.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-326.6% EBITDA margin	Analyst estimates available to subscribers	-159.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$95.5M	Analyst estimates available to subscribers	-$88.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-333.5% EBIT margin	Analyst estimates available to subscribers	-170.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$86.1M	Analyst estimates available to subscribers	-$78.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-300.9% net profit margin	Analyst estimates available to subscribers	-149.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Metagenomi Therapeutics

This financial data table provides comprehensive performance metrics for Metagenomi Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Metagenomi Therapeutics generated $28.6M in revenue over the last twelve months.
The company achieved -$93.5M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$86.1M.

Fiscal Year Performance

In the most recent fiscal year, Metagenomi Therapeutics reported $52.3M in total revenue.
Fiscal year EBITDA was -$83.5M.
The company maintained a gross profit margin of NaN% in the most recent fiscal year.
EBITDA margin for the fiscal year was -159.7%.
Net profit margin reached -149.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Metagenomi Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Metagenomi Therapeutics Stock Performance

Metagenomi Therapeutics has current market cap of $65.0M, and EV of -$77.5M.

Market Cap Evolution

Metagenomi Therapeutics Stock Data

As of January 15, 2026, Metagenomi Therapeutics's stock price is $2.

See Metagenomi Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
-$77.5M	$65.0M	XXX	XXX	XXX	XXX	$-2.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Metagenomi Therapeutics Valuation Multiples

Metagenomi Therapeutics's trades at -2.7x EV/Revenue multiple, and 0.8x EV/EBITDA.

See valuation multiples for Metagenomi Therapeutics and 15K+ public comps

Metagenomi Therapeutics Financial Valuation Multiples

As of January 15, 2026, Metagenomi Therapeutics has market cap of $65.0M and EV of -$77.5M.

Equity research analysts estimate Metagenomi Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Metagenomi Therapeutics has a P/E ratio of -0.8x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$65.0M	XXX	$65.0M	XXX	XXX	XXX
EV (current)	-$77.5M	XXX	-$77.5M	XXX	XXX	XXX
EV/Revenue	-2.7x	XXX	-2.7x	XXX	XXX	XXX
EV/EBITDA	0.8x	XXX	0.8x	XXX	XXX	XXX
EV/EBIT	0.8x	XXX	0.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-0.8x	XXX	-0.8x	XXX	XXX	XXX
EV/FCF	1.1x	XXX	1.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Metagenomi Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Metagenomi Therapeutics Margins & Growth Rates

Metagenomi Therapeutics's last 12 month revenue growth is -11%

Metagenomi Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.

Metagenomi Therapeutics's rule of 40 is -136% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Metagenomi Therapeutics's rule of X is -354% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Metagenomi Therapeutics and other 15K+ public comps

Metagenomi Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	-11%	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	-327%	XXX	-327%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	29%	XXX	XXX	XXX
Rule of 40	-136%	XXX	-337%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-354%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	209%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	270%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial